Literature DB >> 33420361

Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.

Yinyin Xu1,2, Jing Guo3, Jing Liu3, Ying Xie3, Xin Li3, Hongmei Jiang3, Jingjing Wang3, Ziyi Peng3, Jingya Wang3, Sheng Wang3, Chao Wan2, Lanting Chen4, Yuping Zhong5, Beizhong Liu6,7, Zhiqiang Liu8,9.   

Abstract

Myeloma cells produce excessive levels of dickkopf-1 (DKK1), which mediates the inhibition of Wnt signaling in osteoblasts, leading to multiple myeloma (MM) bone disease. Nevertheless, the precise mechanisms underlying DKK1 overexpression in myeloma remain incompletely understood. Herein, we provide evidence that hypoxia promotes DKK1 expression in myeloma cells. Under hypoxic conditions, p38 kinase phosphorylated cAMP-responsive element-binding protein (CREB) and drove its nuclear import to activate DKK1 transcription. In addition, high levels of DKK1 were associated with the presence of focal bone lesions in patients with t(4;14) MM, overexpressing the histone methyltransferase MMSET, which was identified as a downstream target gene of hypoxia-inducible factor (HIF)-1α. Furthermore, we found that CREB could recruit MMSET, leading to the stabilization of HIF-1α protein and the increased dimethylation of histone H3 at lysine 36 on the DKK1 promoter. Knockdown of CREB in myeloma cells alleviated the suppression of osteoblastogenesis by myeloma-secreted DKK1 in vitro. Combined treatment with a CREB inhibitor and the hypoxia-activated prodrug TH-302 (evofosfamide) significantly reduced MM-induced bone destruction in vivo. Taken together, our findings reveal that hypoxia and a cytogenetic abnormality regulate DKK1 expression in myeloma cells, and provide an additional rationale for the development of therapeutic strategies that interrupt DKK1 to cure MM.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33420361      PMCID: PMC7892339          DOI: 10.1038/s41388-020-01590-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

2.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.

Authors:  Shmuel Yaccoby; Wen Ling; Fenghuang Zhan; Ronald Walker; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 3.  [Wnt signaling in myeloma.]

Authors:  Masahiro Abe
Journal:  Clin Calcium       Date:  2019

4.  PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma.

Authors:  Barbara Muz; Maurizio Buggio; Feda Azab; Pilar de la Puente; Mark Fiala; Mahesh V Padval; David T Weaver; Jonathan A Pachter; Ravi Vij; Abdel Kareem Azab
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Hypoxia favors the generation of human plasma cells.

Authors:  Matthieu Schoenhals; Michel Jourdan; Angélique Bruyer; Alboukadel Kassambara; Bernard Klein; Jérôme Moreaux
Journal:  Cell Cycle       Date:  2017-05-02       Impact factor: 4.534

7.  Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Authors:  Deborah J Heath; Andrew D Chantry; Clive H Buckle; Les Coulton; John D Shaughnessy; Holly R Evans; John A Snowden; David R Stover; Karin Vanderkerken; Peter I Croucher
Journal:  J Bone Miner Res       Date:  2009-03       Impact factor: 6.741

8.  Induction of chemoresistance by all-trans retinoic acid via a noncanonical signaling in multiple myeloma cells.

Authors:  Zhiqiang Liu; Tao Li; Kesheng Jiang; Qiaoli Huang; Yicheng Chen; Feng Qian
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

9.  The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways.

Authors:  Huili Zhu; Yusheng Zhang; Zhongshan Shi; Dan Lu; Tingting Li; Yan Ding; Yiwen Ruan; Anding Xu
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

Review 10.  MMSET: role and therapeutic opportunities in multiple myeloma.

Authors:  Zhigang Xie; Wee Joo Chng
Journal:  Biomed Res Int       Date:  2014-07-01       Impact factor: 3.411

View more
  3 in total

Review 1.  Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma.

Authors:  Alessandro Allegra; Marco Casciaro; Paola Barone; Caterina Musolino; Sebastiano Gangemi
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

2.  A Risk-Assessing Signature Based on Hypoxia- and Immune-Related Genes for Prognosis of Lung Adenocarcinoma Patients.

Authors:  Yue Wang; Jian Feng; Yang Liu; Tingyue Han
Journal:  Comput Math Methods Med       Date:  2022-09-28       Impact factor: 2.809

3.  Hyperbaric Oxygen Therapy Does Not Have a Negative Impact on Bone Signaling Pathways in Humans.

Authors:  Zaida Salmón-González; Javier Anchuelo; Juan C Borregán; Alvaro Del Real; Carolina Sañudo; Maria Teresa García-Unzueta; José A Riancho; Carmen Valero
Journal:  Healthcare (Basel)       Date:  2021-12-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.